Research Paper Volume 12, Issue 14 pp 14376—14390
MicroRNA-15a/16/SOX5 axis promotes migration, invasion and inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes
- 1 Division of Rheumatology, Clinical Medical College, Yangzhou University, Jiangsu Province, China
- 2 Division of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province, China
- 3 Division of Rheumatology, The First People’s Hospital of Yancheng, Jiangsu Province, China
- 4 Institute of Integrated Chinese and Western Medicine, Nanjing Medical University, Jiangsu Province, China
- 5 Division of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province, China
Received: February 21, 2020 Accepted: May 27, 2020 Published: July 17, 2020
https://doi.org/10.18632/aging.103480How to Cite
Abstract
Fibroblast-like synoviocytes (FLSs) are key effector cells in the pathogenesis of rheumatoid arthritis (RA) and display a unique aggressive tumor-like phenotype with remarkable hyperplasia, increased cell migration and invasion. How FLSs undergo these changes in RA remains unknown. We previously reported a novel function of transcription factor SOX5 in RA-FLSs that promote cell migration and invasion. In this study, we found that miR-15a/16 directly targets the SOX5 3’UTR and suppresses SOX5 expression. Moreover, miR-15a/16 is significantly down-regulated in RA-FLSs, which negatively correlates with SOX5 expression. Transfection with miR-15a/16 mimics in RA-FLSs inhibits cell migration, invasion, IL-1β and TNFα expression. Overexpression SOX5 in RA-FLSs decreases miR-15a/16 expression and rescues miR-15a/16-mediated inhibitory effect. Furthermore, RA patients with the lower baseline serum miR-15a/16 level present poor response of 3 months disease-modifying antirheumatic drugs (DMARDs) therapy. Collectively, this study reveals that miR-15a/16/SOX5 axis functions as a key driver of RA-FLSs invasion, migration and inflammatory response in a mutual negative feedback loop and correlates with DMARDs treatment response in RA.